XML 39 R19.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Goodwill and Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2023
Goodwill and Intangible Assets |
Goodwill and Intangible Assets | 11. Goodwill and Intangible Assets ​ The Company’s goodwill resulted from the BDSI Acquisition. Refer to Note 4, Acquisitions, for more information. ​ The following tables summarizes the changes in the carrying amount of goodwill: ​
​ | ​ | ​ | ​
​ | ​ | Amount
Balance as of December 31, 2021 | ​ | $ | —
Goodwill resulting from BDSI Acquisition | ​ | ​ | 133,695
Balance as of December 31, 2022 | ​ | $ | 133,695
Measurement period adjustments from BDSI Acquisition | ​ | ​ | 162
Balance as of December 31, 2023 | ​ | $ | 133,857
​ The following table sets forth the cost, accumulated amortization, and carrying amount of intangible assets as of December 31, 2023 and 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | As of December 31, 2023 | ​ | As of December 31, 2022
​ | Amortization Period (Years) | ​ | ​ | Cost | ​ | ​ | Accumulated Amortization | ​ | ​ | Carrying Amount | ​ | ​ | Cost | ​ | ​ | Accumulated Amortization | ​ | ​ | Carrying Amount
Belbuca | 4.8 | ​ | $ | 360,000 | ​ | $ | (133,821) | ​ | $ | 226,179 | ​ | $ | 360,000 | ​ | $ | (58,428) | ​ | $ | 301,572
Nucynta Products (1) | 8.5 | ​ | ​ | 521,170 | ​ | ​ | (382,710) | ​ | ​ | 138,460 | ​ | ​ | 521,170 | ​ | ​ | (319,628) | ​ | ​ | 201,542
Symproic | 9.6 | ​ | ​ | 70,000 | ​ | ​ | (12,931) | ​ | ​ | 57,069 | ​ | ​ | 70,000 | ​ | ​ | (5,646) | ​ | ​ | 64,354
Elyxyb | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,000 | ​ | ​ | (5,000) | ​ | ​ | —
Total intangibles | ​ | ​ | $ | 951,170 | ​ | $ | (529,462) | ​ | $ | 421,708 | ​ | $ | 956,170 | ​ | $ | (388,702) | ​ | $ | 567,468
​ The following table presents amortization and impairment expense recognized in cost of product revenues for the years ended December 31, 2023, 2022, and 2021: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years Ended December 31,
​ |  | ​ | 2023 |  | ​ | 2022 |  | ​ | 2021
Belbuca |  | $ | 75,393 |  | $ | 58,428 |  | $ | —
Nucynta Products (1) | ​ | ​ | 63,082 | ​ | ​ | 67,181 | ​ | ​ | 67,181
Symproic | ​ | ​ | 7,285 | ​ | ​ | 5,646 | ​ | ​ | —
Elyxyb (2) | ​ | ​ | — | ​ | ​ | 5,000 | ​ | ​ | —
Total amortization and impairment expense | ​ | $ | 145,760 | ​ | $ | 136,255 | ​ | $ | 67,181
​
| (1) | During the three months ended September 30, 2023, the United States Food and Drug Administration (“FDA”) granted New Patient Population exclusivity in pediatrics for Nucynta IR which extends the period of U.S. exclusivity for Nucynta IR to July 3, 2026, resulting in an extension of the estimated useful life of the underlying intangible asset from 8.0 years to 8.5 years. This change in estimate resulted in a decrease of amortization expense of $4,099 and an increase in net income of $3,037 during the year ended December 31, 2023. The impact to earnings per share — basic and earnings per share — diluted was $0.09 and $0.07, respectively, during the year ended December 31, 2023.
| (2) | Includes $214 of amortization expense and $4,786 of impairment expense.
​ Intangible Asset Impairment ​ During the three months ended December 31, 2022, the Company made the decision to discontinue the commercialization of Elyxyb. Accordingly, an asset impairment evaluation performed during the three months ended December 31, 2022 resulted in the Company recognizing $4,786 of impairment expense related to the Elyxyb intangible asset, which was equivalent to the carrying amount of the Elyxyb asset at the time of the impairment determination. The impairment expense reflects that no significant proceeds are expected to be realized from its disposition. The impairment expense is included in “Intangible asset amortization and impairment” in the consolidated statements of operations. Other expenses associated with the discontinuation of Elyxyb were immaterial. ​ The revenues generated from sales of Elyxyb to date were immaterial. Elyxyb is not considered a significant component of the entity’s business and therefore, is not presented as a discontinued operation. ​ There were no employees impacted by the decision to discontinue the commercialization of Elyxyb and therefore, no severance or employee benefit expenses were recognized. In addition, contract termination costs related to the discontinuation were immaterial and expensed upon the termination of the contracts. In February 2023, the Company entered into the Elyxyb Sale Agreement with Scilex to transfer to Scilex all assets, rights, and obligations necessary to commercialize Elyxyb in the United States and Canada. ​ As of December 31, 2023, the remaining amortization expense expected to be recognized is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Years ended December 31, | Belbuca | ​ | Nucynta Products | ​ | Symproic | ​ | Total
2024 | $ | 75,393 | ​ | $ | 55,384 | ​ | $ | 7,285 | ​ | $ | 138,062
2025 | ​ | 75,393 | ​ | ​ | 55,384 | ​ | ​ | 7,285 | ​ | ​ | 138,062
2026 | ​ | 75,393 | ​ | ​ | 27,692 | ​ | ​ | 7,285 | ​ | ​ | 110,370
2027 | ​ | — | ​ | ​ | — | ​ | ​ | 7,285 | ​ | ​ | 7,285
2028 | ​ | — | ​ | ​ | — | ​ | ​ | 7,285 | ​ | ​ | 7,285
Thereafter | ​ | — | ​ | ​ | — | ​ | ​ | 20,644 | ​ | ​ | 20,644
Remaining amortization expense | $ | 226,179 | ​ | $ | 138,460 | ​ | $ | 57,069 | ​ | $ | 421,708
​

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration